Decrease of respiratory muscle strength and static lung volumes in obese asthmatics.

E Melzer; J F Souhrada

doi:10.1164/arrd.1980.121.1.17

Home/Archive/PubMed

PubMed · 7352702

Decrease of respiratory muscle strength and static lung volumes in obese asthmatics.

E Melzer·J F Souhrada

View original source ↗Export metadata ↓

Abstract

Ten obese patients with steroid-dependent bronchial asthma were studied. All were female nonsmokers and all had normal chest roentgenograms. The patients were divided into 2 groups according to their total lung capacity (TLC), i.e., those with decreased TLC (N = 4) and those with normal TLC (n = 6). It was found that patients with low TLC had decreased respiratory muscle strength, as measured by maximal inspiratory esophageal pressure, and that the pressure-volume (P-V) curve of the lung was shifted downward and to the right. There were no differences between the 2 groups in degree of airflow limitation, in per cent increase in body weight, and in duration and dose of steroid therapy. All had normal values of diffusion, corrected for alveolar volume. It is concluded that respiratory muscle strength is an important factor in maintaining normal static lung volumes. The data suggest that the combination of obesity and steroid therapy can cause a decrease in respiratory muscle strength in certain obese patients with bronchial asthma. The change in P-V curve seen in the patients with decreased TLC may be secondary to the decrease in static lung volumes.

Explore related subjects

17-Hydroxycorticosteroids Adolescent Adult Airway Resistance Asthma Female Humans Lung Volume Measurements Maximal Expiratory Flow Rate Middle Aged Muscle Hypotonia Muscles Obesity Respiration Total Lung Capacity Vital Capacity Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

E Melzer, J F Souhrada. 1980. Decrease of respiratory muscle strength and static lung volumes in obese asthmatics.. https://doi.org/10.1164/arrd.1980.121.1.17

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1996

Induction of ovulation with the sole use of clomiphene citrate in late-onset 21-hydroxylase deficiency.

Late-onset 21-hydroxylase deficiency (21-OHD) is a congenital enzymatic defect in the glucocorticoid and mineralocorticoid steroidogenic pathways. The manifestations, including hirsutism and infertility, usually occur at puberty or young adulthood. In infertile, anovulatory women with late-onset 21-OHD, the usual therapy is glucocorticoids for ovulation induction. In this case, we report the sole use of clomiphene citrate to induce ovulation in a patient with late-onset 21-OHD. A hirsute and oligomenorrheic woman was diagnosed as having polycystic ovary syndrome at age 25. Her hirsutism responded to oral contraceptives. At age 31, she was given clomiphene citrate alone for ovulation induction and conceived in her fourth cycle. At age 36, because of increased hirsutism she was diagnosed with late-onset 21-OHD by an ACTH stimulation test. The induction of ovulation in late-onset 21-OHD patients has been with glucocorticoids. Given the success in inducing ovulation with clomiphene citrate alone in this patient with well-documented late-onset 21-OHD, it may be worthwhile to study the sole use of clomiphene citrate for ovulation induction in these patients.

17-Hydroxycorticosteroids↗

PubMed1996

Incidentally discovered adrenocortical adenomas are not fully nonfunctioning: immunohistochemical and dispersed adrenocortical cell study.

To clarify the precise function of incidentally discovered adrenocortical adenoma, immunohistochemical and dispersed adrenal cell studies were performed. We have recently seen five patients with so-called nonfunctioning adrenocortical adenoma. Diurnal variation in plasma cortisol and suppression of plasma cortisol and urine 17-hydroxycorticosteroids in response to dexamethasone administration revealed adrenocortical function within normal limits in all cases, and no signs or symptoms of adrenal steroid hormone excess were evident. Since a high uptake of iodomethylnorcholesterol was recognized in each adrenal mass, it was supposed that these adrenal tumors produced steroid hormone to a certain extent, and each patient received unilateral adrenalectomy. P450c17, a key enzyme involved in cortisol production, was expressed in the tumor region in all cases in an immunohistochemical study. Upon in vitro steroidogenesis with dispersed adrenal cells in two cases, all steroid hormones measured except for aldosterone (progesterone, 17 alpha-hydroxyprogesterone, pregnenolone, 17 alpha-hydroxypregnenolone, 11-deoxycortisol, cortisol, 11-deoxycorticosterone, corticosterone, 18-hydroxydeoxycorticosterone, dehydroepiandrosterone and androstenedione) were produced in a culture medium. The results indicated that these tumors possessed the capacity for cortisol production, which was in agreement with the results of an iodomethyl-norcholesterol scintigraphy. All patients with mild hypertension or diabetes mellitus had no signs or symptoms of steroid hormone excess, but they could potentially develop a steroid excess syndrome such as Cushing's syndrome in the future.

17-Hydroxycorticosteroids↗

PubMed1995

Adrenocortical carcinoma. A clinical study and treatment results of 52 patients.

BACKGROUND: Adrenocortical carcinoma is a rare tumor with a poor prognosis. This work was aimed at analyzing the clinical outlook and treatment results of 52 patients with this disease. METHODS: This study included patients with adrenocortical carcinoma referred to the Department of Endocrinology at the Center of Postgraduate Medical Education (Warsaw, Poland) during the last 30 years. In 11 patients, the adrenal tumor was found incidentally by ultrasonographic scan. Hormonal examinations made it possible to define the endocrine activity of the tumors, whereas imaging techniques helped to determine their staging. Forty-eight patients underwent surgery, and 36 of them received mitotane. This drug was administered to 26 patients for a range of 10 months to 10 years; 13 patients received mitotane immediately after the operation, and 13 others after a delay. The patients with severe hypercorticism were pretreated before surgery with aminoglutethimide and mitotane. RESULTS: The study comprised 10 men and 42 women; hormonally active tumors were diagnosed in 39 of them. Cushing's syndrome was the most frequent entity. At diagnosis, 17 cases were classified as localized disease, 15 as regional disease, and 20 as distant disease. Pretreatment with the inhibitors of steroidogenesis improved the survival perspectives in the early postoperative period. As of this writing, there were 12 survivors in the group of 26 patients treated by surgery and long term mitotane therapy and only 2 survivors of 7 patients treated with surgery only. CONCLUSIONS: Surgery with immediate adjuvant long term mitotane administration was the most effective form of therapy for patients with adrenocortical carcinoma.

17-Hydroxycorticosteroids↗